CDK9 and hemoglobin measurement: Two CDK9 inhibitors, namely alvocidib and dinaciclib, were thus identified and extensively validated in vitro and in vivo in PDX mouse models; moreover, CDK9 expression levels were found to be predictive of clinical outcome in a cohort of patients with HB.